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A B ST R AC T 
 
 
Multiple myeloma (MM) is a plasma cell neoplasm, characterized 
by periods of remission and relapses. The emergence of novel 
therapies, with multiple mechanisms of action and fewer adverse 
reactions, brings more and better options and also a higher survival 
rate. However, MM is still an incurable disease, and patients 
eventually become refractory to an extensive range of therapies. We 
present the case of a patient diagnosed with MM standard risk, who 
was at first refractory to multiple treatment regimens, and then had 
an unexpected and stable complete response to a newer drug of the 
same class.   
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Introduction  
Multiple myeloma (MM) is a plasma-cell neoplasm, 
representing 10-13% of hematologic malignancies [1,2]. 
Although it is usually a chronic disorder, and many 
therapies are available, it remains incurable. We present a 
standard risk MM patient, who first was unexpectedly 
refractory to multiple treatment regimens, and then had a 
spectacular and stable response to a newer drug of a 
previously used class. 
Case Presentation 
A 63-years-old male was admitted to our department 
with fatigue and severe low back pain radiating to the lower 
right extremity, non-related to trauma. His past medical 
history was unremarkable, except for anemia discovered 
one-year prior presentation. Physical examination was 
normal, except for pallor. Laboratory analyses are 
displayed in Table 1. Diagnosis was multiple myeloma IgG 
lambda secretory, stage II. Also, he presented an L3-




After establishing the diagnosis, chemotherapy was 
initiated with a melphalan-free regimen with the patient 
eligible for autologous hematopoietic stem cell 
transplantation (auto-HCT). We started CyBorD protocol 
(cyclophosphamide, bortezomib, dexamethasone), without 
significant complications. The L3 vertebral tumor was 
excised. Postoperative histopathological exam confirmed 
the plasmacytoma. Evaluation after four cycles showed 
only partial response (Table 2).  
We proceeded with hematopoietic stem cell collection 
(apheresis from peripheral blood) – 5.17x106 CD34+ 
cells/kg, enough for two auto-HCTs. During 
hospitalization, the patient developed femoral-popliteal 
deep venous thrombosis, complicated with pulmonary 
thromboembolism. He was started on anticoagulants, with 
favorable evolution. 
We continued with another four cycles of CyBorD, 
without complications. Evaluation revealed stable disease 
(Table 2), but far from an appropriate response. The 
transplant team recommended continuing treatment as 
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before, high-dose melphalan and auto-HCT, but because of 
the unsatisfactory response, with another regimen.  
As the patient did not fit the official reimbursement 
criteria for thalidomide, and lenalidomide is not available 
in Romania, the only available regimen was VAD 
(vincristine, doxorubicin, dexamethasone), which 
unfortunately was followed by grave complications: a 
severe infection of the upper left limb, requiring surgical 
intervention, broad-spectrum antibiotics, and a one-month 
hospitalization; two weeks after discharge, he developed 
bronchopneumonia with subsequent septic shock, and 
paroxysmal atrial fibrillation, all requiring again a 
prolonged hospitalization and intensive care. Also, reactive 
depression appeared, necessitating antidepressants. 
Meanwhile, the disease rapidly progressed and even the 
weak response was lost (Table 2). Auto-HCT was delayed 
due to lack of proper disease control, multiple and severe 
infectious complications during chemotherapy, and also by 
patients’ preference. He received three cycles of MP 
(melphalan, prednisone) protocol. 
A few months later, carfilzomib became available. We 
decided to start Kd (carfilzomib, dexamethasone) protocol, 
20 months after diagnosis. Evaluation after four cycles 
showed very good partial response, and after six cycles, a 
complete response (Table 2). Evolution under treatment 
with Kd protocol was favorable. Currently, the patient is at 
cycle 24, maintaining CR, and with no other complications 
except for mild hematological toxicity.  
 
Table 1. Laboratory findings at diagnosis 
Laboratory tests (normal 
ranges) 
Patients’ findings 
Complete Blood count 











































Laboratory findings at diagnosis 
Laboratory tests (normal 
ranges) 
Patients’ findings 
Serum immunofixation test 
IgG-λ monoclonal 
protein 
IgG (700-1600mg/dL) 2416.5mg/dL 
Serum protein electrophoresis 
   Gamma-globulins (11-21%) 




Cytogenetic examination del17p- 
C-reactive protein (0-5mg/L) 1.36mg/L 
Proteinuria/24 h 625.28mg/24 h 




Whole body CT-scan Multiple well-defined 
lytic lesions, 
predominantly 
located in the 
vertebral bodies and 
in the pelvis 
Magnetic Resonance Imaging L3 vertebral tumor, 
with intracanalicular 
extension and severe 
compression; diffuse 
and focal alterations 
in bone structure 
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Table 2: Evolution of hematological parameters 
Laboratory tests Month 6 
(4 CyBorD) 





(+3 MP +4 Kd) 
Month 27 
(+2 Kd) 
Serum total protein 9.4g/dL 9.2g/dL 10.8g/dL 6.8g/dL 6.7g/dL 
Gamma globulin 35.4% 34.4% 44.7% 19.4% 6.2% 
IgG 3430mg/dL 4073mg/dL 6786mg/dL 1255mg/dL 883mg/dL 
Serum immunofixation  positive positive positive positive negative 
Proteinuria negative - negative negative negative 
Bone marrow plasma cells - 2% - 1% undetectable 
Discussions 
Life expectancy in MM depends on the response to 
therapy. It has increased in parallel with the emergence of 
novel therapies with various mechanisms of action [1,3,4]. 
The clinical evolution of MM, as with other 
lymphoproliferative disorders [5,6,7] is marked by periods 
of remission and relapse, the latter becoming more frequent 
and more aggressive with each regimen [1,4]. Despite the 
multiple options available, MM is still incurable, and 
patients ultimately become refractory to a broad spectrum 
of drugs [1]. 
Proteasome inhibitors are an effective treatment of MM 
[8]. Here, we used a bortezomib-based regimen as first-
line, approved for transplant eligible patients. Our patient 
first had only an insufficient partial response, and later 
became refractory – aggressive MM although the initial 
prognosis markers were not unfavorable (standard risk, 
stage II). Since no other options were available at the time, 
we chose VAD regimen. We administered only one cycle 
when severe, life-threatening infectious complications 
appeared (after a less intensive protocol than the previous 
one). We decided to use a regimen with lower toxicity, 
melphalan-based, as stem cells were already collected. No 
response was observed after any of those regimens. When 
carfilzomib became available, though the patient had a 
refractory disease with a high and progressive burden and 
multiple previous complications, we decided to continue 
treatment with Kd regimen. The response was extremely 
favorable and mostly unexpected: stable CR and no 
adverse reactions whatsoever.  
It is known that carfilzomib has greater selectivity and 
irreversibly inhibits the proteasome, and thus responses 
may appear even in bortezomib-refractory patients [8]. 
However, median progression free survival (PFS) for Kd 
regimen in bortezomib-exposed patients with 2-3 previous 
treatment lines, is 13.1months [9]. Our patient already has 
a double PFS and maintains response. Also, CR rates 
reported for Kd combination even in standard risk patients 
are actually quite low (13.0%) [10].   
So, after the unexpected inadequate first response, our 
patient surprised us again with such a favorable outcome: 
CR and prolonged PFS at Kd, without notable adverse 
reactions, in a patient treated with three lines and previous 
severe complications. 
Highlights 
✓ Unexpected favorable and durable response to a newer 
drug of the same class that was inefficient as first line, 
in a patient who had become refractory provides 
renewed hope for the patient, as newer and more 
effective drugs are constantly being developed. 
Conclusions 
We aim to illustrate hereby the case of a patient who 
did not have an unfavorable prognosis at diagnosis by 
using the known markers, and yet responded poorly and 
progressed under standard therapy. But, he had the chance 
to benefit from a newer drug, although from the same class 
as the one to which he had already showed resistance. 
Nevertheless, he showed an unexpected complete and 
stable response, beyond what statistics might have 
predicted.  
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